Cidara Therapeutics (NASDAQ:CDTX) and BIO-TECHNE (NASDAQ:TECH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
This table compares Cidara Therapeutics and BIO-TECHNE’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cidara Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, BIO-TECHNE has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Cidara Therapeutics and BIO-TECHNE, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cidara Therapeutics currently has a consensus target price of $7.60, indicating a potential upside of 347.06%. BIO-TECHNE has a consensus target price of $201.25, indicating a potential downside of 3.85%. Given Cidara Therapeutics’ higher probable upside, research analysts plainly believe Cidara Therapeutics is more favorable than BIO-TECHNE.
BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.6%. Cidara Therapeutics does not pay a dividend. BIO-TECHNE pays out 31.4% of its earnings in the form of a dividend.
Insider and Institutional Ownership
60.3% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 92.7% of BIO-TECHNE shares are owned by institutional investors. 15.3% of Cidara Therapeutics shares are owned by insiders. Comparatively, 3.8% of BIO-TECHNE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Cidara Therapeutics and BIO-TECHNE’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cidara Therapeutics||N/A||N/A||-$59.02 million||($2.32)||-0.73|
|BIO-TECHNE||$642.99 million||12.33||$126.15 million||$4.07||51.43|
BIO-TECHNE has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.
BIO-TECHNE beats Cidara Therapeutics on 11 of the 15 factors compared between the two stocks.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.